Press Releases

Inari Medical Announces the Release of 2022 Ethos and Sustainability Report

May 25, 2023

IRVINE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2022 Ethos and Sustainability Report.

Inari Medical Announces PEERLESS II, a Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System vs. Anticoagulation in Pulmonary Embolism Patients

May 22, 2023

IRVINE, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced planned enrollment of the PEERLESS II trial, Inari’s third

Inari Medical Reports First Quarter 2023 Financial Results

May 3, 2023

IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2023.

Inari Medical to Present at the Bank of America 2023 Healthcare Conference

May 2, 2023

IRVINE, Calif., May 02, 2023 (GLOBE NEWSWIRE) --  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the Bank of America

Inari Medical to Announce First Quarter 2023 Financial Results

April 13, 2023

IRVINE, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its first quarter 2023 financial

FLAME Study Demonstrates 90% Survival Improvement in High-Risk Pulmonary Embolism with Inari Medical FlowTriever System

March 6, 2023

IRVINE, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced positive results from the FLAME study in high-risk/massive

Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results

February 27, 2023

IRVINE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended

Inari Medical to Announce Fourth Quarter and Full Year 2022 Financial Results

February 7, 2023

IRVINE, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its fourth quarter and full year 2022

Inari Medical to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 31, 2023

IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will participate virtually at the

Inari Medical Announces First Patient Enrolled in the DEFIANCE Trial, Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis

January 12, 2023

IRVINE, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that the first patient has been enrolled in DEFIANCE, a